No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
295 |
4. Check minimum number of eventsNone |
295 |
5. Include endpointsNone |
295 |
6. Filter based on genotype QC (FinnGen only) |
291 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D18
- Name in latin
- Lymphangioma (quovis hoco)
Similar endpoints
↥List of similar endpoints to
Lymphangioma, anys site
based on the number of shared cases.
Similar with more cases:
- Haemangioma and lymphangioma, any site
- Benign neoplasms
- Neoplasms
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2976 | 1458 | 1511 |
| Only index persons | 2551 | 1253 | 1298 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.04 | 0.04 | 0.04 |
| Only index persons | 0.05 | 0.05 | 0.05 |
| Median age at first event (years) | |||
| Whole population | 16.06 | 17.67 | 14.29 |
| Only index persons | 18.56 | 20.72 | 16.47 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 291 | 177 | 114 |
| Unadjusted period prevalence (%) | 0.06 | 0.06 | 0.05 |
| Median age at first event (years) | 31.94 | 33.05 | 30.22 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 295
- Matched controls
- 2950
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D18.1
ICD-10 Finland
Lymphangioma, any site
11433.7
300.5
236
*
D18.0
ICD-10 Finland
Haemangioma, any site
24.8
74.1
55
27
22701
ICD-8 Finland
Haemangioma and lymphangioma, Lymphangioma
+∞
38.4
36
*
2281A
ICD-9 Finland
Haemangioma and lymphangioma, any site, Lymphangioma, any site
+∞
38.4
36
*
R22.1
ICD-10 Finland
Localized swelling, mass and lump, neck
11.0
33.7
38
39
QX3LT
NOMESCO Finland
Subcutaneous sclerotherapy
202.3
18.8
19
*
WX408
NOMESCO Finland
General anesthesy, balanced
2.9
15.7
103
462
QX2XE
NOMESCO Finland
Ultrsound examination of soft tissue not elsewhere classified
7.3
15.1
23
34
EP1LT
NOMESCO Finland
Percutaneous sclerotherapy of vascular malformation of head and neck
+∞
13.6
13
*
Q27.4
ICD-10 Finland
Congenital phlebectasia
146.5
13.6
14
*
EP1CG
NOMESCO Finland
Extensive MRI examination of soft tissue of neck with high intesity magnet
19.1
12.2
18
10
Q27.9
ICD-10 Finland
Congenital malformation of peripheral vascular system, unspecified
113.9
10.5
11
*
22700
ICD-8 Finland
Haemangioma and lymphangioma, Haemangioma
56.9
9.7
11
*
Q18.0
ICD-10 Finland
Sinus, fistula and cyst of branchial cleft
16.2
9.1
14
9
XX6KT
NOMESCO Finland
Other sclerotherapy
37.9
9.1
11
*
ZXE10
NOMESCO Finland
More than one and less than three hours
2.1
8.5
115
684
J01CE08
ATC
benzathine benzylpenicillin; parenteral
17.8
8.1
12
7
ZXD10
NOMESCO Finland
Scheduled procedure
2.0
7.9
119
732
QX3HE
NOMESCO Finland
Ultrsound examination of lesion close to skin
8.8
7.9
16
19
Q27.88
ICD-10 Finland
Other specified congenital malformation of peripheral vascular system
82.1
7.5
8
*
4704
FHL
Neck tumor removal
82.1
7.5
8
*
9736
FHL
Subcutaneous tumor removal in operating room or anesthesia
13.8
7.4
12
9
EP1AT
NOMESCO Finland
Punction of soft tissue of neck with ultrasound guidance
+∞
7.3
7
*
ENB40
NOMESCO Finland
Excision of branchial cyst or fistula
30.8
7.2
9
*
WX404
NOMESCO Finland
Intravenous generell anesthesy
2.2
6.9
71
376
Q18.8
ICD-10 Finland
Other specified congenital malformations of face and neck
71.3
6.5
7
*
QAA40
NOMESCO Finland
Laser therapy or photocoagulation of skin of head or neck
71.3
6.5
7
*
ZXE20
NOMESCO Finland
More than three and less than five hours
2.4
6.3
45
203
PG1DE
NOMESCO Finland
Other extensive ultrasound examination of artery
3.8
6.3
19
52
EP1DG
NOMESCO Finland
Very extensive examination of soft tissue of neck with high intesity magnet
18.5
6.3
9
5
Q27.3
ICD-10 Finland
Peripheral arteriovenous malformation
27.3
6.3
8
*
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
3.4
6.0
22
69
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
10
6
17.17
6.79
1.3
3.0
129.10
145.50
%
—
10
6
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
10
12
8.58
5.10
1.4
2.0
113.00
121.58
%
—
10
12
121
849
1.72
4.79
9.4
11.3
1.17
1.18
inr
0.08
37
273
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
9
11
8.40
4.59
2.0
1.1
86.33
124.82
%
—
9
11
176
1385
1.67
4.39
10.2
9.1
3.88
4.02
e9/l
0.45
160
1214
9
13
7.10
4.19
1.0
1.5
8.86
9.80
umol/l
—
9
13
142
1074
1.62
4.03
2.6
2.6
—
—
—
0
0
13
44
3.04
3.17
1.5
1.3
6.20
3.85
u/ml
—
5
20
200
1694
1.56
3.15
8.8
6.9
79.35
80.94
u/l
0.22
193
1589
8
16
5.11
3.07
1.3
1.4
—
—
—
0
0
14
52
2.78
2.93
1.1
1.2
—
—
—
0
0
119
914
1.51
2.90
2.7
2.4
77.66
73.57
nmol/l
0.85
112
830
75
522
1.59
2.84
2.5
2.2
—
—
—
0
0
130
1028
1.47
2.70
8.4
7.6
1.21
1.22
mmol/l
0.90
116
878
12
43
2.87
2.68
1.3
1.2
—
—
—
0
0
28
156
1.88
2.35
7.8
4.7
0.71
1.21
mmol/l
0.39
22
115
110
867
1.43
2.23
6.5
4.9
36.60
36.58
g/l
0.02
105
815
26
147
1.84
2.10
1.2
1.5
—
—
—
0
0
11
43
2.62
2.10
1.6
1.3
1.20
1.47
u/ml
—
5
17
5
10
5.06
2.08
1.0
1.2
79.60
82.51
u/l
—
5
10
5
10
5.06
2.08
1.0
1.2
15.40
32.67
u/l
—
5
10
70
514
1.47
2.04
3.0
2.3
2.01
1.18
mg/l
0.38
56
394
9
32
2.87
2.01
1.0
1.2
—
—
—
0
0
5
12
4.22
1.83
1.2
1.0
—
—
—
0
0
9
36
2.55
1.75
1.0
1.1
—
—
—
0
0
5
13
3.89
1.72
3.8
2.5
24.40
27.85
umol/l
—
5
13
11
49
2.29
1.65
1.0
1.3
—
—
—
0
0
257
2412
1.51
1.57
15.3
11.9
25.57
22.22
mg/l
0.69
213
1817
92
742
1.35
1.55
4.0
3.3
26.90
33.94
ng/l
0.31
61
445
14
72
1.99
1.51
2.1
1.9
—
—
—
0
0
12
58
2.11
1.51
1.1
1.2
—
—
—
0
0
12
58
2.11
1.51
2.1
2.4
—
—
—
0
0
6
21
2.89
1.51
1.2
1.1
—
—
—
0
0
228
2100
1.38
1.50
13.1
10.6
89.00
89.06
ml/min/173m2
0.01
195
1672
9
37
2.48
1.49
1.0
1.5
—
—
—
0
0
7
28
2.54
1.46
1.0
1.3
—
—
—
0
0
13
66
2.01
1.45
2.1
1.8
—
—
—
0
0
5
16
3.16
1.44
4.6
1.8
—
—
—
0
0
149
1299
1.30
1.42
4.9
5.3
6.31
6.53
mmol/l
0.86
141
1186
7
29
2.45
1.40
1.3
1.8
—
—
—
0
0
34
234
1.51
1.37
5.0
8.6
105.59
104.47
mmol/l
0.81
34
234
28
186
1.56
1.32
3.6
3.0
—
—
—
0
0
25
162
1.59
1.31
1.9
2.6
85.13
72.42
ml/min/173m2
—
8
69
110
933
1.29
1.26
7.8
7.4
1.20
1.22
mmol/l
0.97
100
855
6
25
2.43
1.25
1.0
1.2
—
—
—
0
0
10
49
2.08
1.23
1.4
1.5
—
—
—
0
0
10
49
2.08
1.23
2.6
1.5
0.35
0.46
nmol/l
—
10
40
32
223
1.49
1.23
3.4
6.2
1.63
1.67
mmol/l
0.02
26
168
189
1725
1.27
1.14
4.3
3.8
10.67
10.19
mm/h
0.20
173
1577
91
762
1.28
1.14
2.0
1.8
95.81
96.96
pmol/l
0.08
55
375
199
1830
1.27
1.12
4.2
3.8
14.67
14.59
pmol/l
0.18
181
1680
7
32
2.22
1.09
1.3
1.7
—
—
—
0
0
29
205
1.46
1.06
1.4
1.2
68.99
141.33
iu/ml
—
8
74
247
2342
1.34
1.04
16.7
13.4
3.94
3.94
mmol/l
0.03
242
2262
27
189
1.47
1.03
10.5
9.2
25.47
24.90
mmol/l
0.40
27
189
9
47
1.94
1.03
1.1
1.3
—
—
—
0
0
9
47
1.94
1.03
1.1
1.3
—
—
—
0
0
30
219
1.41
0.94
4.7
10.8
-0.03
0.90
mmol/l
0.71
22
173
10
170
0.57
0.93
1.2
1.3
—
—
—
0
0
6
28
2.17
0.92
1.0
1.3
—
—
—
0
0
6
28
2.17
0.92
1.0
1.3
—
—
—
0
0
6
28
2.17
0.92
1.0
1.3
—
—
—
0
0
6
28
2.17
0.92
1.0
1.3
—
—
—
0
0
5
103
0.48
0.91
1.4
1.6
—
—
—
0
0
6
29
2.09
0.90
1.0
1.2
—
—
—
0
0
14
87
1.64
0.89
1.9
2.3
38.93
42.55
u/l
0.30
14
79
6
31
1.95
0.85
1.3
1.5
—
—
—
0
0
281
2738
1.55
0.83
23.1
17.5
39.94
40.56
%
1.01
267
2605
41
325
1.30
0.79
1.7
1.8
—
—
—
0
0
9
55
1.66
0.74
1.3
1.8
—
—
—
0
0
5
25
2.02
0.73
1.0
1.0
—
—
—
0
0
7
40
1.77
0.71
1.1
1.0
—
—
—
0
0
228
2172
1.22
0.71
4.9
4.5
1.65
1.83
mu/l
2.59
214
2016
7
43
1.64
0.67
1.3
1.9
—
—
—
0
0
10
62
1.63
0.66
1.4
1.4
316.80
277.92
ug/g
—
5
35
16
223
0.70
0.65
1.5
1.5
—
—
—
0
0
45
371
1.25
0.65
2.0
1.7
417.90
446.85
pmol/l
0.37
40
318
87
768
1.19
0.65
3.3
3.1
—
—
—
0
0
5
29
1.74
0.64
1.4
1.8
—
—
—
0
0
5
29
1.74
0.64
1.4
1.8
—
—
—
0
0
225
2149
1.20
0.64
3.8
3.5
1.18
1.27
mmol/l
1.37
215
2007
5
30
1.68
0.61
3.2
2.0
—
—
—
0
0
79
697
1.18
0.59
4.0
3.1
2.35
2.36
mmol/l
0.25
71
609
0
22
0.00
0.59
0.0
1.6
—
2.22
—
0
9
6
36
1.68
0.57
3.2
5.1
—
4848.00
—
0
5
20
152
1.34
0.53
4.0
3.3
1.21
1.23
mmol/l
1.20
20
127
9
63
1.44
0.53
1.1
1.4
—
—
—
0
0
231
2225
1.18
0.52
4.2
3.9
1.50
1.46
mmol/l
0.58
220
2079
11
155
0.70
0.50
1.2
1.5
—
—
—
0
0
7
47
1.50
0.48
1.4
2.4
3.30
5.34
u/ml
—
7
47
15
112
1.36
0.45
3.1
2.7
0.22
0.21
e6/l
0.01
15
106
40
466
0.84
0.45
4.5
4.1
1.89
1.80
ug/l
0.08
35
426
234
2265
1.16
0.44
4.4
4.2
2.76
2.82
mmol/l
0.50
224
2113
58
653
0.86
0.44
1.7
1.7
—
—
—
0
0
198
1898
1.13
0.43
3.2
3.6
—
—
—
0
0
47
409
1.18
0.43
1.3
1.3
10.68
22.34
iu/ml
2.20
16
131
8
57
1.41
0.42
1.3
1.8
—
—
—
0
0
8
58
1.39
0.42
1.3
1.8
—
—
—
0
0
16
123
1.32
0.41
2.5
2.6
21.06
37.30
u/ml
0.75
16
118
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
1.16
—
0
10
7
105
0.66
0.40
1.1
1.5
—
—
—
0
0
0
19
0.00
0.39
0.0
1.7
—
—
—
0
0
0
19
0.00
0.39
0.0
1.7
—
—
—
0
0
0
19
0.00
0.39
0.0
1.7
—
—
—
0
0
207
1995
1.13
0.39
5.4
4.8
38.41
38.68
mmol/mol
0.17
198
1872
13
98
1.34
0.38
1.5
1.5
—
—
—
0
0
37
320
1.18
0.37
1.9
1.7
1331.03
1226.48
nmol/l
0.17
32
236
5
80
0.62
0.36
1.2
1.6
—
—
—
0
0
69
628
1.13
0.35
2.8
3.0
0.48
0.35
e6/l
0.25
53
462
10
73
1.38
0.35
1.0
1.2
0.12
3.09
u/ml
—
5
45
6
89
0.67
0.33
2.3
1.4
—
—
—
0
0
223
2168
1.12
0.32
4.4
3.8
5.77
5.77
mmol/l
0.01
208
1992
54
487
1.13
0.32
2.1
2.4
—
—
—
0
0
50
450
1.13
0.31
2.0
2.2
—
—
—
0
0
7
54
1.30
0.30
1.4
1.8
211.14
240.04
pmol/l
—
7
49
7
55
1.28
0.30
1.4
1.2
—
—
—
0
0
27
233
1.17
0.28
1.5
1.7
—
—
—
0
0
230
2246
1.11
0.28
4.3
3.9
4.65
4.70
mmol/l
0.35
221
2111
9
74
1.22
0.25
1.1
2.6
—
—
—
0
0
6
84
0.71
0.24
2.0
1.6
—
—
—
0
0
73
683
1.09
0.23
1.5
1.4
2.92
1.18
u/ml
0.42
20
164
5
38
1.32
0.23
2.0
1.5
—
—
—
0
0
31
276
1.14
0.23
1.6
1.9
—
—
—
0
0
7
92
0.76
0.23
1.0
1.1
—
—
—
0
0
5
40
1.25
0.22
1.4
1.9
—
—
—
0
0
5
40
1.25
0.22
1.4
1.8
—
—
—
0
0
0
11
0.00
0.21
0.0
1.9
—
—
—
0
0
0
10
0.00
0.21
0.0
2.0
—
—
—
0
0
0
10
0.00
0.21
0.0
2.0
—
—
—
0
0
0
10
0.00
0.21
0.0
2.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.8
—
—
—
0
0
0
12
0.00
0.21
0.0
1.8
—
—
—
0
0
0
12
0.00
0.21
0.0
4.9
—
—
—
0
0
11
134
0.81
0.21
1.6
1.5
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
89
845
1.08
0.20
3.7
3.2
—
—
—
0
0
6
48
1.26
0.20
3.3
3.9
55.50
54.90
%
—
6
48
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
10
122
0.81
0.19
1.9
1.9
—
—
—
0
0
11
90
1.23
0.19
1.5
6.2
0.90
0.66
%
0.89
11
90
12
100
1.21
0.18
1.6
1.3
—
—
—
0
0
5
67
0.74
0.17
2.2
1.4
—
104.25
—
0
12
8
69
1.16
0.16
7.8
2.5
—
—
—
0
0
13
111
1.18
0.16
1.2
1.9
—
—
—
0
0
6
80
0.74
0.15
1.0
1.2
—
—
—
0
0
56
531
1.07
0.13
4.1
3.8
17.76
8.74
mg/mmol
0.42
38
341
35
374
0.93
0.12
3.2
3.7
17.18
22.16
%
1.36
16
135
42
397
1.07
0.11
1.3
1.3
3.01
8.43
u/ml
1.11
18
153
40
378
1.07
0.11
3.4
3.3
22.59
216.07
ng/l
2.70
29
260
10
87
1.15
0.09
1.0
1.1
—
9.49
—
0
14
55
572
0.95
0.09
2.0
1.7
1.25
1.36
mmol/l
0.63
50
498
45
431
1.05
0.08
1.5
1.5
—
—
—
0
0
116
1136
1.03
0.08
3.7
3.3
0.00
0.00
estimate
-0.00
18
208
11
123
0.89
0.08
1.5
1.4
—
—
—
0
0
11
123
0.89
0.08
1.5
1.4
—
—
—
0
0
11
123
0.89
0.08
1.5
1.5
—
—
—
0
0
11
123
0.89
0.08
1.5
1.5
—
—
—
0
0
56
580
0.96
0.08
3.4
3.3
0.00
0.00
estimate
0.50
15
218
7
68
1.03
0.08
1.1
1.4
—
—
—
0
0
7
82
0.85
0.07
1.0
1.1
—
—
—
0
0
114
1119
1.03
0.07
5.4
4.6
0.00
0.00
estimate
-0.00
18
222
17
158
1.08
0.06
1.5
1.3
—
44.87
—
0
9
25
237
1.06
0.06
1.5
1.7
—
—
—
0
0
28
267
1.05
0.05
1.7
1.6
—
—
—
0
0
25
238
1.06
0.05
6.4
6.0
—
—
—
0
0
36
372
0.96
0.04
2.6
2.8
1.15
2.76
e6/l
2.01
18
194
27
280
0.96
0.03
2.4
2.5
0.62
0.75
ug/l
0.57
16
159
12
128
0.93
0.02
1.8
1.3
—
—
—
0
0
21
218
0.96
0.02
1.4
1.8
—
—
—
0
0
38
388
0.98
0.01
2.6
2.6
1.46
0.86
e6/l
0.34
20
208
12
119
1.01
0.00
1.1
1.4
228.44
299.02
miu/ml
—
6
63
18
183
0.98
0.00
5.7
10.0
1.78
1.26
mmol/l
0.60
18
177
18
175
1.03
0.00
1.1
1.0
—
—
—
0
0
112
1122
1.00
0.00
3.7
3.2
0.00
0.00
estimate
0.50
20
232
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
3.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.6
—
1.21
—
0
7
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
5
50
1.00
0.00
2.0
1.6
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
96.43
—
0
7
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
20.65
—
0
8
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
49
1.02
-0.00
15.8
3.6
28.78
35.94
mg/l
—
5
40
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
4.8
—
23.60
—
0
5
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
5
49
1.02
-0.00
15.8
3.6
195.96
25.50
mg/l
—
5
40
8
84
0.95
-0.00
1.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
5.3
—
—
—
0
0
6
62
0.97
-0.00
2.0
1.5
—
0.04
—
0
11
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
49
1.02
-0.00
15.8
3.6
—
1.50
—
0
6
Mortality – FinRegistry
↥Association
Association between endpoint CD2_BENIGN_LYMPHANGIOMA and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CD2_BENIGN_LYMPHANGIOMA | 1.448 [1.07, 1.96] | 0.017 |
| Birth year | 0.992 [0.98, 1.0] | 0.092 |
During the follow-up period (1.1.1998 — 31.12.2019), 67 out of 980 females with CD2_BENIGN_LYMPHANGIOMA died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CD2_BENIGN_LYMPHANGIOMA | 1.548 [1.15, 2.08] | 0.004 |
| Birth year | 0.985 [0.97, 1.0] | 0.007 |
During the follow-up period (1.1.1998 — 31.12.2019), 77 out of 1096 males with CD2_BENIGN_LYMPHANGIOMA died.
Mortality risk
Mortality risk for people of age
years, who have CD2_BENIGN_LYMPHANGIOMA.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.107% | 0.272% |
| 5 | 0.651% | 1.425% |
| 10 | 1.786% | 3.827% |
| 15 | 3.482% | 7.045% |
| 20 | 6.277% | 12.193% |
Relationships between endpoints
↥Index endpoint: CD2_BENIGN_LYMPHANGIOMA – Lymphangioma, anys site
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data